Extended access to rufinamide for eligible participants
Part of Brain & nervous system, Genetic & congenital clinical trials.
This program provides continued access to rufinamide for people who finished a specific study in Poland and were receiving rufinamide. It ensures you can keep taking the medication while it is still being evaluated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in and completed study E2080-G000-303 in Poland.
- You must have been receiving rufinamide during that study.
- You were not assigned to the other medication group in that study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives patients with Fabry disease who took part in a previous study the chance to continue receiving the study treatment, lucerastat, after that study ends. It aims to provide uninterrupted care while longer-term safety and effects are monitored.
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
This trial offers continued access to the study drug ATH434 for people in France who finished a previous study (ATH434-201) and may still benefit from treatment. It aims to provide ongoing care while monitoring safety and effects.
This trial provides continued access to fremanezumab for children and teens who have already completed a related study. It aims to offer ongoing treatment safely under a doctor's supervision.
This trial lets people who completed a prior anifrolumab study and saw benefit continue receiving the drug. It monitors long-term safety and effectiveness.
This expanded access program offers the combination of NRX-101 and theta burst transcranial magnetic stimulation (TMS) for people with treatment-resistant depression who cannot participate in a related clinical trial. It aims to provide treatment access while monitoring safety and effectiveness.
Hear when a new Lennox Gastaut Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.